You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

~ Buy the ODEFSEY (emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate) Drug Profile, 2024 PDF Report in the Report Store ~

odefsey Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Odefsey patents expire, and what generic alternatives are available?

Odefsey is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and thirty-one patent family members in fifty-seven countries.

The generic ingredient in ODEFSEY is emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate profile page.

DrugPatentWatch® Generic Entry Outlook for Odefsey

Odefsey was eligible for patent challenges on November 5, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 15, 2033. This may change due to patent challenges or generic licensing.

There have been nineteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for odefsey?
  • What are the global sales for odefsey?
  • What is Average Wholesale Price for odefsey?
Summary for odefsey
Drug patent expirations by year for odefsey
Drug Prices for odefsey

See drug prices for odefsey

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for odefsey
Generic Entry Date for odefsey*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for ODEFSEY
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ODEFSEY Tablets emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate 200 mg/25 mg/ 25 mg 208351 3 2019-11-05

US Patents and Regulatory Information for odefsey

odefsey is protected by four US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of odefsey is ⤷  Subscribe.

This potential generic entry date is based on patent ⤷  Subscribe.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences Inc ODEFSEY emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate TABLET;ORAL 208351-001 Mar 1, 2016 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y Y ⤷  Subscribe
Gilead Sciences Inc ODEFSEY emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate TABLET;ORAL 208351-001 Mar 1, 2016 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Gilead Sciences Inc ODEFSEY emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate TABLET;ORAL 208351-001 Mar 1, 2016 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Gilead Sciences Inc ODEFSEY emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate TABLET;ORAL 208351-001 Mar 1, 2016 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for odefsey

International Patents for odefsey

When does loss-of-exclusivity occur for odefsey?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Patent: 39
Patent: TENOFOVIR ALAFENAMIDE HEMIFUMARATE
Estimated Expiration: ⤷  Subscribe

Argentina

Patent: 7546
Patent: HEMIFUMARATO DE TENOFOVIR ALAFENAMIDA
Estimated Expiration: ⤷  Subscribe

Australia

Patent: 12296622
Patent: Tenofovir alafenamide hemifumarate
Estimated Expiration: ⤷  Subscribe

Patent: 14271320
Patent: TENOFOVIR ALAFENAMIDE HEMIFUMARATE
Estimated Expiration: ⤷  Subscribe

Brazil

Patent: 2014003420
Patent: hemifumarato de tenofovir alafenamida
Estimated Expiration: ⤷  Subscribe

Canada

Patent: 45553
Patent: HEMIFUMARATE DE TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
Estimated Expiration: ⤷  Subscribe

Chile

Patent: 14000370
Patent: Hemifumarato de tenofovir alafenamida; metodo de preparación; composicion farmaceutica que lo comprende; metodo para preparar la composicion farmaceutica; y uso en el tratamiento de una infeccion por hiv.
Estimated Expiration: ⤷  Subscribe

China

Patent: 3732594
Patent: Tenofovir alafenamide hemifumarate
Estimated Expiration: ⤷  Subscribe

Patent: 0343135
Patent: 替诺福韦艾拉酚胺(TENOFOVIR ALAFENAMIDE)半反丁烯二酸盐 (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
Estimated Expiration: ⤷  Subscribe

Colombia

Patent: 80063
Patent: Hemifumarato de tenofovir alafenamida
Estimated Expiration: ⤷  Subscribe

Costa Rica

Patent: 140072
Patent: HEMIFUMARATO DE TENOFOVIR ALAFENAMIDA
Estimated Expiration: ⤷  Subscribe

Croatia

Patent: 0161696
Estimated Expiration: ⤷  Subscribe

Cyprus

Patent: 18385
Estimated Expiration: ⤷  Subscribe

Denmark

Patent: 44810
Estimated Expiration: ⤷  Subscribe

Ecuador

Patent: 14013206
Patent: HEMIFUMARATO DE TENOFOVIR ALAFENAMIDA
Estimated Expiration: ⤷  Subscribe

Eurasian Patent Organization

Patent: 7768
Patent: ТЕНОФОВИР АЛАФЕНАМИДА ГЕМИФУМАРАТ (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
Estimated Expiration: ⤷  Subscribe

Patent: 1490208
Patent: ТЕНОФОВИР АЛАФЕНАМИДА ГЕМИФУМАРАТ
Estimated Expiration: ⤷  Subscribe

European Patent Office

Patent: 44810
Patent: HÉMIFUMARATE DE TÉNOFOVIR ALAFÉNAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
Estimated Expiration: ⤷  Subscribe

Patent: 70088
Patent: TÉNOFOVIR ALAFENAMIDE HÉMIFUMARATE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
Estimated Expiration: ⤷  Subscribe

Patent: 31832
Patent: TÉNOFOVIR ALAFENAMIDE HÉMIFUMARATE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
Estimated Expiration: ⤷  Subscribe

Finland

Patent: 44810
Estimated Expiration: ⤷  Subscribe

Hong Kong

Patent: 99026
Patent: 替諾福韋艾拉酚胺 半反丁烯二酸鹽 (TENOFOVIR ALAFENAMIDE HEMIFUMARATE (TENOFOVIRALAFENAMIDE))
Estimated Expiration: ⤷  Subscribe

Hungary

Patent: 31253
Estimated Expiration: ⤷  Subscribe

India

Patent: 12DEN2014
Estimated Expiration: ⤷  Subscribe

Israel

Patent: 0949
Patent: טנופוביר אלאפנאמיד המיפומאראט (Tenofovir alafenamide hemifumarate)
Estimated Expiration: ⤷  Subscribe

Japan

Patent: 51275
Estimated Expiration: ⤷  Subscribe

Patent: 56537
Estimated Expiration: ⤷  Subscribe

Patent: 80162
Estimated Expiration: ⤷  Subscribe

Patent: 14528924
Patent: テノホビルアラフェナミドヘミフマレート
Estimated Expiration: ⤷  Subscribe

Patent: 15038149
Patent: テノホビルアラフェナミドヘミフマレート (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
Estimated Expiration: ⤷  Subscribe

Patent: 16169228
Patent: テノホビルアラフェナミドヘミフマレート (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
Estimated Expiration: ⤷  Subscribe

Patent: 18065870
Patent: テノホビルアラフェナミドヘミフマレート (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
Estimated Expiration: ⤷  Subscribe

Patent: 20040972
Patent: テノホビルアラフェナミドヘミフマレート (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
Estimated Expiration: ⤷  Subscribe

Lithuania

Patent: 44810
Estimated Expiration: ⤷  Subscribe

Mexico

Patent: 6627
Patent: HEMIFUMARATO DE TENOFOVIR ALAFENAMIDA. (TENOFOVIR ALAFENAMIDE HEMIFUMARATE.)
Estimated Expiration: ⤷  Subscribe

Patent: 14001549
Patent: HEMIFUMARATO DE TENOFOVIR ALAFENAMIDA. (TENOFOVIR ALAFENAMIDE HEMIFUMARATE.)
Estimated Expiration: ⤷  Subscribe

Moldova, Republic of

Patent: 08
Patent: Hemifumarat de tenofovir alafenamidă şi utilizările sale medicale (Tenofovir alafenamide hemifumarate and its medical uses)
Estimated Expiration: ⤷  Subscribe

Patent: 140011
Patent: Tenofovir alafenamid hemifumarat (Tenofovir alafenamide hemifumarate)
Estimated Expiration: ⤷  Subscribe

Montenegro

Patent: 612
Patent: TENOFOVIR ALAFENAMID HEMIFUMARAT (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
Estimated Expiration: ⤷  Subscribe

Morocco

Patent: 350
Patent: Hemifumarate de tenofovir alafenamide
Estimated Expiration: ⤷  Subscribe

New Zealand

Patent: 0421
Patent: Tenofovir alafenamide hemifumarate
Estimated Expiration: ⤷  Subscribe

Peru

Patent: 141328
Patent: TENOFOVIR ALAFENAMIDA HEMIFUMARATO
Estimated Expiration: ⤷  Subscribe

Poland

Patent: 44810
Estimated Expiration: ⤷  Subscribe

Portugal

Patent: 44810
Estimated Expiration: ⤷  Subscribe

San Marino

Patent: 01600476
Patent: TENOFOVIR ALAFENAMMIDE EMIFUMARATO
Estimated Expiration: ⤷  Subscribe

Serbia

Patent: 353
Patent: TENOFOVIR ALAFENAMID HEMIFUMARAT (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
Estimated Expiration: ⤷  Subscribe

Singapore

Patent: 14011548
Patent: TENOFOVIR ALAFENAMIDE HEMIFUMARATE
Estimated Expiration: ⤷  Subscribe

Slovenia

Patent: 44810
Estimated Expiration: ⤷  Subscribe

South Africa

Patent: 1400582
Patent: TENOFOVIR ALAFENAMIDE HEMIFUMARATE
Estimated Expiration: ⤷  Subscribe

South Korea

Patent: 1612642
Estimated Expiration: ⤷  Subscribe

Patent: 140054068
Patent: TENOFOVIR ALAFENAMIDE HEMIFUMARATE
Estimated Expiration: ⤷  Subscribe

Spain

Patent: 08871
Estimated Expiration: ⤷  Subscribe

Taiwan

Patent: 16499
Estimated Expiration: ⤷  Subscribe

Patent: 1321396
Patent: Tenofovir alafenamide hemifumarate
Estimated Expiration: ⤷  Subscribe

Ukraine

Patent: 5311
Patent: ГЕМІФУМАРАТ ТЕНОФОВІРУ АЛАФЕНАМІДУ (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
Estimated Expiration: ⤷  Subscribe

Uruguay

Patent: 262
Patent: HEMIFUMARATO DE TENOFOVIR ALAFENAMIDA, SUS COMPOSICIONES, MÉTODO DE PREPARACIÓN, MÉTODOS PARA TRATAR INFECCIONES VIRALES Y SU USO PARA PREPARAR MEDI CAMENTOS
Estimated Expiration: ⤷  Subscribe

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering odefsey around the world.

Country Patent Number Title Estimated Expiration
Australia 3397901 ⤷  Subscribe
Eurasian Patent Organization 200400304 ПРОИЗВОДНЫЕ ПИРИМИДИНА, ИНГИБИРУЮЩИЕ ВИЧ ⤷  Subscribe
Japan 4922937 ⤷  Subscribe
Poland 1632232 ⤷  Subscribe
Eurasian Patent Organization 013686 ГИДРОХЛОРИД 4-[[4-[[4-(2-ЦИАНОЭТЕНИЛ)-2,6-ДИМЕТИЛФЕНИЛ]АМИНО]-2-ПИРИМИДИНИЛ]АМИНО]БЕНЗОНИТРИЛА (HYDROCHLORIDE OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL] AMINO]BENZONITRILE) ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for odefsey

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1663240 2015/054 Ireland ⤷  Subscribe PRODUCT NAME: A COMBINATION OF RILPIVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE HYDROCHLORIDE SALT, AND TENOFOVIR, IN PARTICULAR TENOFOVIR DISOPROXIL FUMARATE; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
1663240 93383 Luxembourg ⤷  Subscribe PRODUCT NAME: COMBINAISON DE RILPIVIRINE OU UNE FORME THERAPEUTIQUE EQUIVALENTE QUI EN DERIVE TELLE QUE PROTEGEE PAR LE BREVET DE BASE, TEL QU'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE RILPIVIRINE, INCLUANT LE SEL CHLORHYDRATE DE RILPIVIRINE,EMTRICITABINE, ET TENOFOVIR ALAFENAMIDE, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE FUMARATE DE TENOFOVIR ALAFENAMIDE; AUTHORISATION NUMBER AND DATE: EU/1/16/1112 ODEFSEY - EMTRICITABINE
1419152 CA 2012 00019 Denmark ⤷  Subscribe
3808743 2290034-4 Sweden ⤷  Subscribe PRODUCT NAME: A COMBINATION OF RILPIVRINE OR A THERAPEUTICALLY EQIVALENT FORM THEREOF PROTECTED BY THE BASIC PATENT, SUCH AS A PHARMACEUTICALLY ACCEPTABLE ADDITION SALT OF RILPIVIRINE, INCLUDING THE HYDROCHLORIC ACID SALT OF RILPIVIRINE, AND EMTRICITABINE; REG. NO/DATE: EU/1/11/737/001-002 20111128
1301519 C01301519/01 Switzerland ⤷  Subscribe PRODUCT NAME: TENOFOVIRALAFENAMID; REGISTRATION NO/DATE: SWISSMEDIC AUTHORISATION 65793 01.09.2016
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Odefsey Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Odefsey

Introduction to Odefsey

Odefsey is a combination antiretroviral therapy (ART) developed by Gilead Sciences, consisting of emtricitabine, rilpivirine, and tenofovir alafenamide (TAF). It is used for the treatment of HIV-1 infection in adults and children weighing at least 35 kg.

Market Positioning of Odefsey

Competitive Landscape

In the HIV-1 treatment market, Gilead Sciences dominates with a significant market share. Odefsey, along with other Gilead products like Biktarvy, Genvoya, and Descovy, plays a crucial role in this dominance. However, the market is highly competitive, with ViiV Healthcare being another major player, holding a 21% market share in 2020[1].

Shift from TDF to TAF-Based Regimens

The HIV-1 treatment market has seen a significant shift from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) based regimens. Odefsey, being a TAF-based regimen, has benefited from this trend. For instance, the sales of Odefsey increased significantly after its launch, capturing a substantial market share. In 2018, Odefsey generated $1.242 billion in sales in the US, which is a notable figure compared to its TDF-based counterpart, Complera, which saw a decline in sales during the same period[1].

Financial Performance of Odefsey

Sales Trends

Odefsey has shown strong sales performance since its launch. However, its sales have been impacted by the rise of other Gilead products, particularly Biktarvy. Despite this, Odefsey remains a significant contributor to Gilead's HIV product portfolio. In 2018, Odefsey's sales were $1.242 billion, but these figures began to decline as Biktarvy gained market share. By 2020, Odefsey's sales had reduced, reflecting the market's preference for Biktarvy due to its excellent safety and efficacy profile[1].

Impact of Biktarvy on Odefsey Sales

Biktarvy, approved in 2018, has been a game-changer in the HIV-1 treatment market. Its market size in the launch year was $1.144 billion, which increased to $6.095 billion by 2020. This rapid uptake has led to a decline in the sales of other HIV-1 therapies, including Odefsey. The market dominance of Biktarvy is expected to continue, with projected sales of $10.673 billion by 2024, making it challenging for Odefsey and other therapies to regain significant market share[1].

Patent Expiry and Generic Competition

The HIV-1 treatment market is set to face significant changes due to patent expiries. While Odefsey itself is not yet facing patent expiry, the loss of exclusivity for other key products like Truvada and Atripla in 2020 has already impacted the market. The upcoming patent expiries of other major HIV drugs, such as Descovy and Complera/Eviplera in 2025, will introduce generic competition, potentially affecting the sales of branded products like Odefsey[1].

Global Market Dynamics

Growth Drivers

The global HIV treatment market, including Odefsey, is driven by several factors:

  • Advancements in Medical Technology: Continuous research and development of more effective and tolerable antiretroviral treatments (ARTs).
  • Increased Availability and Affordability: Growing availability and affordability of ARTs.
  • Awareness and Prevention Efforts: Enhanced HIV screening and testing initiatives.
  • Government Funding and Initiatives: Increased government funding and public-private partnerships[4].

Challenges and Opportunities

The COVID-19 pandemic has had a mixed impact on the HIV treatment market. While it disrupted medication supply chains and patient care, it also accelerated pharmaceutical innovation and increased public health awareness. Post-COVID, the market is expected to see improved access to care, increased innovation, and a focus on health equity[4].

Financial Trajectory of Gilead Sciences

Gilead Sciences, the manufacturer of Odefsey, has seen significant financial fluctuations in recent years, largely due to the impact of COVID-19 and the launch of Veklury (remdesivir). In 2020, Gilead's total product sales increased by 10% to $24.4 billion, driven primarily by Veklury sales. However, excluding Veklury, product sales decreased due to lower HCV sales and the expected decline in sales of Truvada-based products following the loss of exclusivity[2].

HIV Product Sales

In the second quarter of 2021, HIV product sales decreased by 2% to $3.9 billion compared to the same period in 2020, reflecting the loss of exclusivity for Truvada and Atripla. However, this decline was partially offset by the continued uptake of Biktarvy and other HIV therapies[3].

Future Outlook

The future outlook for Odefsey and the broader HIV-1 treatment market is shaped by several factors:

  • Emerging Therapies: New therapies like lenacapavir, VH184, and bNAbs are expected to enter the market, potentially altering the competitive landscape.
  • Generic Competition: The introduction of generic substitutes following patent expiries will increase competition.
  • Market Growth: The global HIV treatment market is projected to grow at a CAGR of 1.42% from 2023 to 2030, driven by advancements in ARTs and increased awareness[4].

Key Takeaways

  • Odefsey is a significant player in the HIV-1 treatment market, benefiting from the shift to TAF-based regimens.
  • The rise of Biktarvy has impacted Odefsey's sales, but it remains a crucial part of Gilead's HIV product portfolio.
  • Patent expiries and generic competition will shape the future market dynamics.
  • The global HIV treatment market is expected to grow, driven by advancements in ARTs and increased awareness.

FAQs

What is Odefsey used for?

Odefsey is a combination antiretroviral therapy used for the treatment of HIV-1 infection in adults and children weighing at least 35 kg.

How has the market for Odefsey evolved?

The market for Odefsey has evolved with a shift from TDF to TAF-based regimens, but its sales have been impacted by the rise of Biktarvy.

What are the key drivers of the global HIV treatment market?

The key drivers include advancements in medical technology, increased availability and affordability of ARTs, enhanced HIV screening and testing initiatives, and government funding and initiatives.

How has the COVID-19 pandemic affected the HIV treatment market?

The pandemic has disrupted supply chains and patient care but also accelerated pharmaceutical innovation and increased public health awareness.

What is the future outlook for Odefsey and the HIV-1 treatment market?

The future outlook is shaped by emerging therapies, generic competition, and continued market growth driven by advancements in ARTs and increased awareness.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.